Cipher Pharmaceuticals
Focus: Cipher Pharmaceuticals is a public-stage specialty pharma company headquartered in Mississauga, ON, focused on small-molecule therapeutics primarily in neurology. The company derives 99% of revenue from a single product, QINLOCK (ripretinib), a KIT receptor inhibitor for gastrointestinal stromal tumors.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
0
About Cipher Pharmaceuticals
AI assessmentNot HiringNo open roles listed right now. Follow Cipher Pharmaceuticals to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
3/9 — Basic
Company HealthSolid
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
$52M Part DStable
Peak16.4yr
Sole revenue driver and primary cash generator with 17-year patent runway; represents company's entire business model.
Help build intelligence for Cipher Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.